October 14, 2020 - levitronix.com · October 14, 2020 10am EST / 16:00 CET ... Single-use (SU)...
Transcript of October 14, 2020 - levitronix.com · October 14, 2020 10am EST / 16:00 CET ... Single-use (SU)...
October 14, 2020 10am EST / 16:00 CET
Status as of 30/09/[email protected] www.levitronix.com/LBC2020
For more information
Oakwood has an aseptic process for manufacturing polymer-based biodegradable microspheres for the sustained
release of pharmaceuticals. Levitronix pumps and flow meters are utilized in various aspects of our continuous
manufacturing process. An overview of Oakwood’s microsphere manufacturing process will be presented with
several examples of different sustained release formulations. The impact of switching from traditional peristaltic
pumps to Levitronix pumps will be discussed.
Samantha Cramer works as a Formulations Engineer at Oakwood Labs, with more than 10 years of experience in industry. Samantha started her role at Oakwood Labs in 2016 working to develop and scale-up controlled release microsphere based formulations. Throughout her career she has encapsulated small molecules and various peptides. She also spent 3 years at the Cleveland Clinic Lerner Research Institute. Samantha holds a Master’s Degree from Cleveland State University and a Bachelor of Science from Purdue University.
Oakwood Labs
Formulations Engineer III
Samantha Cramer Using Levitronix pumps in various unit operations of the microsphere manufacturing process
SPEAKERS
SPEAKERS
Single-use (SU) components are increasingly used for the production of biologics, and many production steps
have successfully shifted from stainless steel to SU components. In the cell harvest, however, current technologies
struggle to keep up with the increasing demand for larger batch volumes and higher cell densities. Depth filters,
for instance, require too many modules and have a huge footprint, in addition to being susceptible to turbidity
breakthrough.
The CONTIBAC® SU filtration technology of DrM excels where other technologies crumble, due to introducing two
novel concepts in the field:
Cake (dead-end) filtration: The filter medium does not perform the filtration, but it acts as a support for the
filter cake consisting of cells and filter aid. As a result, the filtration is much faster, and the filter medium can be
regenerated by back-flushing from the opposite side.
Cyclic operation: Since the filter medium can be regenerated, the filter can be operated in a cyclic fashion as
will be explained in the webinar.
In the webinar it is demonstrated that the aforementioned filtration concepts allow for achieving unprecedented
filtration rates without sacrificing filtrate quality. It will be discussed what percentage of impurities such as host
cell proteins or DNA can be removed during the filtration, and how the flow rates and impurity removal can be
altered using pH adjustments.
Tizian Bucher has been leading the research and development department at Dr. Müller AG for 1.5 years. His key responsibilities are to develop new products in the field of filtration and mixing based on theoretical, experimental and numerical studies. Moreover, he strives to close the gap between fundamental research and product development.
He earned a B.S., M.S., and Ph.D. degree in mechanical engineering from Columbia University in New York. The focus of his M.S. was in mechanics and system identification & control, while the focus of his Ph.D. was in laser manufacturing. He also participated in several research projects that were at the intersection between biomedical and mechanical engineering.
Dr. Mueller AG
R&D Engineer
Dr. Tizian Bucher Cell Harvest using Cyclical Cake Filtration
1
2
SPEAKERS
Oncolytic virotherapy has been recognized as a promising new therapy for cancer for decades but only few viruses
have been approved worldwide. The therapeutic potential of oncolytic viruses can be severely restricted by innate
and adaptive immune barriers making oncolytic virus clinically inefficient.
To overcome this obstacle, we utilized human adipose-derived stem cells (AD-MSC) loaded with tumor selective
CAL1 oncolytic vaccinia virus to generate a new therapeutic agent called SNV1 (SuperNova-1). SNV1 cell-based
platform protects and potentiates oncolytic vaccinia virus by circumventing humoral innate and adaptive immune
barriers, resulting in enhanced oncolytic virotherapy.
Thomas Herrmann works as Director, Translational R&D and Manufacturing at StemVac GmbH. He has more than 10 years of experience in process development of manufacturing and purification processes for vaccinia virus. He also developed up- and downstream processes for infected human adipose derived stem cells which will be used as Trojan horses for vaccinia virus to treat cancer. Under his supervision final processes were transferred to contract manufacturer for GMP production. He worked more than 6 years as a research and senior scientist at Genelux GmbH where he was responsible for the production of new recombinant vaccinia viruses which were used in an inter- company project in molecular PET diagnostics of tumors financed by the BMBF.
After receiving his PhD in Biochemistry at the University of Wuerzburg, he worked as a research scientist at the Department of Clinical Neurobiology at the University Clinics of Wuerzburg for 5 years. During this time he studied changes in axon growth of motor neurons in transgenic animal models for spinal muscular atrophy.
StemVac GmbH, Director
Translational R&D and
Manufacturing
Thomas Herrmann Trojan horses fighting cancer: The next level in oncolytic virus therapy